glycerylphosphorylcholine has been researched along with Alzheimer Disease in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, J; Choi, D; Choi, S; Jeong, S; Kim, K; Kim, SM; Lee, G; Park, SM; Son, JS | 1 |
| Androsova, LV; Gavrilova, SI; Kolykhalov, IV | 1 |
| Alfonsetti, M; Antonosante, A; Benedetti, E; Castelli, V; Catanesi, M; Cimini, A; d'Angelo, M; Desideri, G; Ferri, C | 1 |
| Bernardini, R; Burgaletto, C; Cantarella, G; Di Benedetto, G; Munafò, A | 1 |
| Amenta, F; Carotenuto, A; Fasanaro, AM; Rea, R; Traini, E | 2 |
| Amenta, F; Carotenuto, A; Fasanaro, AM; Manzo, V; Rea, R; Traini, E | 1 |
| Amenta, F; Carotenuto, A; Fasanaro, AM; Manzo, V; Rea, R; Ricci, G; Traini, E | 1 |
| Chan, A; Shea, TB; Suchy, J | 1 |
| Forster, DM; James, MF; Williams, SR | 1 |
| Amenta, F; Tayebati, SK | 1 |
| De Jesus Moreno Moreno, M | 1 |
| Bodick, N; Offen, WW; Renshaw, PF; Satlin, A | 1 |
| Blusztajn, JK; Farber, SA; Slack, BE | 1 |
| Blusztajn, JK; Growdon, JH; Nitsch, RM; Pittas, AG; Slack, BE; Wurtman, RJ | 1 |
| Blusztajn, JK; Growdon, JH; Nitsch, R; Pittas, A; Slack, BE; Wurtman, RJ | 1 |
| Blusztajn, JK; Growdon, JH; Logue, M; Lopez Gonzalez-Coviella, I; Wurtman, RJ | 1 |
| Arús, C; Bárány, M; Chang, YC; Frey, WH; Rustan, T | 1 |
1 review(s) available for glycerylphosphorylcholine and Alzheimer Disease
| Article | Year |
|---|---|
Choline-containing phospholipids: relevance to brain functional pathways.
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Choline; Cholinergic Neurons; Glycerylphosphorylcholine; Humans; Neurodegenerative Diseases; Neuroglia; Phospholipids | 2013 |
6 trial(s) available for glycerylphosphorylcholine and Alzheimer Disease
| Article | Year |
|---|---|
The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Antipsychotic Agents; Donepezil; Double-Blind Method; Female; Glycerylphosphorylcholine; Humans; Indans; Longitudinal Studies; Male; Mental Status Schedule; Middle Aged; Piperidines; Severity of Illness Index | 2014 |
Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.
Topics: Aged; Alzheimer Disease; Apathy; Caregivers; Cholinergic Agents; Donepezil; Double-Blind Method; Drug Therapy, Combination; Female; Glycerylphosphorylcholine; Humans; Indans; Male; Piperidines; Psychiatric Status Rating Scales; Psychotropic Drugs; Time Factors; Treatment Outcome | 2015 |
The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.
Topics: Aged; Alzheimer Disease; Anxiety; Apathy; Caregivers; Depression; Donepezil; Double-Blind Method; Female; Glycerylphosphorylcholine; Humans; Indans; Male; Piperidines; Psychotropic Drugs; Severity of Illness Index; Stress, Psychological; Treatment Outcome | 2017 |
The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Disorders; Donepezil; Double-Blind Method; Female; Follow-Up Studies; Glycerylphosphorylcholine; Humans; Indans; Male; Mental Status Schedule; Middle Aged; Nootropic Agents; Piperidines; Treatment Outcome | 2012 |
Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinergic Agents; Cognition; Double-Blind Method; Female; Glycerylphosphorylcholine; Humans; Male; Mental Status Schedule; Middle Aged; Treatment Outcome | 2003 |
Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.
Topics: Acetylcholine; Alzheimer Disease; Brain; Choline; Creatine; Dose-Response Relationship, Drug; Drug Administration Schedule; Frontal Lobe; Glycerylphosphorylcholine; Humans; Magnetic Resonance Spectroscopy; Muscarinic Antagonists; Neurons; Parasympathetic Nervous System; Protons; Pyridines; Thiadiazoles | 1997 |
11 other study(ies) available for glycerylphosphorylcholine and Alzheimer Disease
| Article | Year |
|---|---|
Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biological Monitoring; Cohort Studies; Female; Glycerylphosphorylcholine; Humans; Male; Middle Aged; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Stroke | 2021 |
[Clinical and immunological effects of choline alfoscerate in the treatment of amnestic type Mild Cognitive Impairment].
Topics: Aged; Alzheimer Disease; Cognition; Cognitive Dysfunction; Glycerylphosphorylcholine; Humans; Middle Aged; Neuropsychological Tests | 2022 |
Neuroprotective potential of choline alfoscerate against β-amyloid injury: Involvement of neurotrophic signals.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apoptosis; Brain-Derived Neurotrophic Factor; Cell Differentiation; Cell Line, Tumor; Cell Survival; Glycerylphosphorylcholine; Humans; Neurons; Neuroprotective Agents; Peptide Fragments; Receptor, trkB; Signal Transduction | 2020 |
Beneficial Effects of Choline Alphoscerate on Amyloid-β Neurotoxicity in an In vitro Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Differentiation; Glycerylphosphorylcholine; Humans; In Vitro Techniques; Mice; Neurons; Peptide Fragments; Phosphorylation; tau Proteins | 2021 |
Dietary supplementation with a combination of alpha-lipoic acid, acetyl-L-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain and improves cognitive performance.
Topics: Acetylcarnitine; Alzheimer Disease; Animals; Antioxidants; Apolipoproteins E; Cognition Disorders; Dietary Supplements; Docosahexaenoic Acids; Drug Therapy, Combination; Folic Acid Deficiency; Glycerylphosphorylcholine; Iron; Maze Learning; Mice; Mice, Knockout; Nootropic Agents; Oxidative Stress; Phosphatidylserines; Reactive Oxygen Species; Thioctic Acid; Vitamin E Deficiency | 2009 |
Effects of Alzheimer's disease transgenes on neurochemical expression in the mouse brain determined by ¹H MRS in vitro.
Topics: Alzheimer Disease; Analysis of Variance; Animals; Aspartic Acid; Biomarkers; Brain; Choline; Glycerylphosphorylcholine; Humans; Inositol; Magnetic Resonance Spectroscopy; Mice; Mice, Transgenic; Transgenes | 2012 |
Acceleration of phosphatidylcholine synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: a model of the membrane defect of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Choline; Cytidine Diphosphate Choline; Dinitrophenols; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glycerylphosphorylcholine; Membranes; Mitochondria; Neurons; PC12 Cells; Phosphatidylcholines; Phosphorylcholine; Rats; Sodium Azide; Time Factors; Uncoupling Agents | 2000 |
Evidence for a membrane defect in Alzheimer disease brain.
Topics: Aged; Alzheimer Disease; Brain; Brain Chemistry; Choline; Down Syndrome; Glycerylphosphorylcholine; Humans; Huntington Disease; Membrane Lipids; Middle Aged; Parkinson Disease; Phospholipids; Phosphoric Diester Hydrolases; Phosphorylcholine | 1992 |
Alterations of phospholipid metabolites in postmortem brain from patients with Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Glycerylphosphorylcholine; Humans; Phosphatidylethanolamines; Phosphoric Diester Hydrolases | 1991 |
Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients.
Topics: Aged; Alzheimer Disease; Brain; Down Syndrome; Female; Glycerylphosphorylcholine; Humans; Male; Middle Aged; Nerve Degeneration; Phosphatidylethanolamines | 1990 |
Increased glycerol-3-phosphorylcholine in post-mortem Alzheimer's brain.
Topics: Alzheimer Disease; Brain Chemistry; Glycerylphosphorylcholine; Humans; Magnetic Resonance Spectroscopy | 1985 |